An observational study in Partial-Onset Seizures and Primary Generalized Tonic-clonic Seizures, sponsored by Eisai Co., Ltd.. Recruiting at 1 site in Japan. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Eisai Co., Ltd. · Observational
The purpose of this study is to determine the safety of Fycompa for injection after administration in participants with epilepsy (partial-onset seizures [including secondarily generalized seizures]) (age 4 years or older) or primary generalized tonic-clonic seizures (age 12 years or older).
766 studies on the registry are indexed under Seizures; 136 are open to participants now.
This study's planned enrollment of 110 is below the median of 140 across 216 observational studies indexed under Seizures.
Browse Seizures studies →Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants with epilepsy who received the Fycompa for injection for the first time will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: No Intervention
This is a non-interventional study.
Number of Participants with Adverse Drug Reactions (ADRs) and Adverse Events (AEs)
Time frame: Up to 4 weeks
Number of Participants With ADRs Based on Participant Characteristic
Time frame: Up to 4 weeks
Plasma Concentration of Fycompa in Children Aged Greater Than or Equal to (>=) 4 Years and Less than (<) 12 Years
Time frame: Up to 4 weeks
Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jun 2028, 42 months after the start.
Of 27 industry-sponsored observational studies under Seizures, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 42 months is above that.
Counting every sponsor, half of 80 studies reached it within 38 months; a quarter within 18 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.